Ian Clements Biography and Net Worth

Ian Clements, Ph.D., has served as chief financial officer since January 2020. Prior to this he served as senior vice president finance and communications and our principal financial and accounting officer since March 2019.

Prior to joining Mirum, Ian served as vice president of investor relations at Dermira, Inc. from May 2017 to March 2019. Ian served as vice president, investor relations and corporate communications at Tobira from July 2015 to December 2016. Prior to that, he was head of investor relations and corporate communications at Avanir Pharmaceuticals from 2011 to June 2015. Ian has also held leadership positions at Sequenom, a genetic analysis and diagnostics company, and The Trout Group, where he managed west coast operations for life sciences investor relations.

Ian received a Ph.D. in chemistry from the University of Manchester, an M.B.A. from the Open University in the United Kingdom and a B.Sc. in chemistry from Staffordshire University.

What is Ian Clements' net worth?: The estimated net worth of Ian Clements is at least $258,757.59 as of December 23rd, 2020. Dr. Clements owns 6,279 shares of Mirum Pharmaceuticals stock worth more than $258,758 as of December 30th. This net worth evaluation does not reflect any other assets that Dr. Clements may own. Learn More about Ian Clements' net worth.
How do I contact Ian Clements?: The corporate mailing address for Dr. Clements and other Mirum Pharmaceuticals executives is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. Mirum Pharmaceuticals can also be reached via phone at (650) 667-4085 and via email at [email protected]. Learn More on Ian Clements' contact information.
Has Ian Clements been buying or selling shares of Mirum Pharmaceuticals?: Ian Clements has not been actively trading shares of Mirum Pharmaceuticals over the course of the past ninety days. Most recently, on Friday, November 26th, Ian Clements bought 750 shares of Mirum Pharmaceuticals stock. The stock was acquired at an average cost of $13.90 per share, with a total value of $10,425.00. Learn More on Ian Clements' trading history.
Who are Mirum Pharmaceuticals' active insiders?: Mirum Pharmaceuticals' insider roster includes Ian Clements (CFO), James Flynn (Major Shareholder), Christopher Peetz (Co-Founder, CEO and Director), and Pamela Vig (Insider). Learn More on Mirum Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Mirum Pharmaceuticals?: During the last twelve months, Mirum Pharmaceuticals insiders bought shares 4 times. They purchased a total of 4,345 shares worth more than $115,064.40. During the last twelve months, insiders at the sold shares 10 times. They sold a total of 51,636 shares worth more than $1,657,025.44. The most recent insider tranaction occured on November, 14th when SVP Jolanda Howe sold 2,500 shares worth more than $117,750.00. Insiders at Mirum Pharmaceuticals own 22.9% of the company. Learn More about insider trades at Mirum Pharmaceuticals.
Information on this page was last updated on 11/14/2024.

Ian Clements Insider Trading History at Mirum Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/26/2021	Buy	750	$13.90	$10,425.00
11/24/2021	Buy	700	$14.40	$10,080.00
10/1/2021	Sell	1,574	$19.26	$30,315.24
12/23/2020	Buy	2,470	$18.61	$45,966.70	6,279
9/6/2019	Buy	4,000	$11.51	$46,040.00

Ian Clements Buying and Selling Activity at Mirum Pharmaceuticals

Mirum Pharmaceuticals Company Overview

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Today's Range

Now: $41.21

$40.93

$41.97

50 Day Range

MA: $42.41

$38.42

$46.65

2 Week Range

Now: $41.21

$23.14

$48.89

Volume

47,447 shs

Average Volume

538,900 shs

Market Capitalization

$1.98 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

Altcoin season moves fast, and those who hesitate are left behind. The window is closing.

>> Register for the Workshop Now